4,876 results match your criteria: "Tardive Dyskinesia"

Clonazepam has some evidence in the treatment of tardive dyskinesia. It can be used as an alternative treatment option in situations where vesicular monoamine transporter 2 inhibitors are not available or when it is not feasible to use them.

View Article and Find Full Text PDF

Immunosenescence-related T cell phenotypes and white matter in schizophrenia patients with tardive dyskinesia.

Schizophr Res

July 2024

Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, PR China. Electronic address:

Schizophrenia patients with tardive dyskinesia (TD) are associated with accelerated biological aging, immunological dysfunction, and premature morbidity and mortality. Older individuals are particularly vulnerable to TD development. As a characteristic of immunosenescence, alterations in the relative proportions of naïve or memory T cell subpopulations may be negatively or positively associated with brain structure abnormalities; however, whether these changes are correlated with TD remains unclear.

View Article and Find Full Text PDF

Analysis of schizophrenia-associated genetic markers in the HLA region as risk factors for tardive dyskinesia.

Hum Psychopharmacol

July 2024

Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.

Objectives: The pathology of Tardive Dyskinesia (TD) has yet to be fully understood, but there have been proposed hypotheses for the cause of this condition. Our team previously reported a possible association of TD with the Complement Component C4 gene in the HLA region. In this study, we explored the HLA region further by examining two previously identified schizophrenia-associated HLA-region single-nucleotide polymorphisms (SNPs), namely rs13194504 and rs210133.

View Article and Find Full Text PDF

Background: Valbenazine is used for tardive movement disorders in adults. Current studies on its safety are mostly from clinical trials and small case reports, limiting information on rare adverse reactions. This study investigated valbenazine-related adverse event (AE) risk signals using the U.

View Article and Find Full Text PDF

Clozapine Prescripers-Dogmatic or Pragmatic?

Psychopharmacol Bull

April 2024

Alhazeem, MD, Faculty of Medicine, Kuwait University, Kuwait.

Clozapine, amongst antipsychotics, has a unique composite mode of action that might translate into an expanded therapeutic potential on clinical grounds. Sorely, clozapine remains underutilized.

View Article and Find Full Text PDF

Introduction: Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia (TD) and chorea associated with Huntington disease (HD). To enhance detection of safety signals across individual trials, integrated safety analyses of deutetrabenazine in TD and HD chorea were conducted.

Methods: For TD, safety data were integrated from two 12-week pivotal studies (ARM-TD and AIM-TD) and through week 15 of the open-label extension (OLE) study (RIM-TD).

View Article and Find Full Text PDF

Tardive dyskinesia (TD) is an involuntary muscle movement typically caused by prolonged exposure to antipsychotic medications. Depending on the symptom severity and the affected body parts, it can cause a terrible decline in patients' daily activities and life quality. TD often persists despite discontinuation of the offending drugs.

View Article and Find Full Text PDF

Pharmacotherapy is an effective treatment modality across psychiatric disorders. Nevertheless, many patients discontinue their medication at some point. Evidence-based guidance for patients, clinicians, and policymakers on rational discontinuation strategies is vital to enable the best, personalized treatment for any given patient.

View Article and Find Full Text PDF
Article Synopsis
  • * Anticholinergic medications can effectively treat conditions like drug-induced parkinsonism and dystonia but are not suitable for tardive dyskinesia, akathisia, or neuroleptic malignant syndrome.
  • * Caution is advised when prescribing anticholinergics due to their potential serious side effects, especially in older patients; they should be used at the lowest effective dose and tapered off gradually.
View Article and Find Full Text PDF
Article Synopsis
  • - Tardive Dyskinesia (TD) is a neurological disorder causing involuntary movements, often due to medications that block dopamine receptors, but VMAT2 inhibitors like valbenazine and deutetrabenazine show promise as effective treatments.
  • - A thorough review of clinical trials found that both deutetrabenazine and valbenazine significantly improved symptoms of TD in patients, particularly noted through improvements in AIMS scores, with minimal adverse effects reported.
  • - Overall, the analysis indicates that VMAT2 inhibitors are safe and effective treatment options for TD, highlighting their potential benefits in diverse populations with low risks of serious side effects.
View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on Minimum Clinically Important Difference (MCID), which is the smallest change in a measure that has real clinical significance, helping with treatment assessment and outcome measure development.
  • The systematic review analyzed 2763 reports, ultimately including 32 studies, with most being of good quality, and highlighted the Unified Parkinson's Disease Rating Scale (UPDRS) as the most frequently evaluated.
  • The review provides a comprehensive list of MCID thresholds for various scales used in movement disorders, emphasizing the importance of standardized MCID measures for future research.
View Article and Find Full Text PDF

Purpose: This post hoc analysis investigated whether a patient's underlying psychiatric disease (schizophrenia/schizoaffective disorder [SCHZ] or bipolar disorder/depressive disorder [MOOD]) influenced the efficacy or safety of valbenazine for tardive dyskinesia (TD) in an Asian population.

Methods: We analyzed data from J-KINECT, a multicenter, phase II/III, randomized, double-blind study, which consisted of a 6-week placebo-controlled period followed by a 42-week extension where Japanese patients with TD received once-daily 40- or 80-mg valbenazine. We compared the change from baseline in Abnormal Involuntary Movement Scale total score and Clinical Global Impression of TD score between patients with SCHZ and those with MOOD, and incidence of treatment-emergent adverse events.

View Article and Find Full Text PDF

Tardive dyskinesia (TD) is a movement disorder that can arise as a side effect of treatment with dopamine receptor-blocking agents (DRBAs), including antipsychotic drugs (APDs) used to manage psychotic illnesses. Second-generation APDs (SGAs) are often preferred to first-generation drugs due to their lower propensity to cause TD, however many SGAs-treated patients still develop the condition. Although TD is a global health concern, evidence regarding the occurrence of TD and how it is managed in Asian countries is currently limited.

View Article and Find Full Text PDF

The differential diagnosis of chorea encompasses a broad range of disorders. In psychiatry, tardive dyskinesia may be difficult to discern from other causes, particularly when the family history is negative. A 59-year-old man with an unclear medical history had been using risperidone for over a decade when we first saw him.

View Article and Find Full Text PDF

Tardive dyskinesia's under-recognition in the era of COVID-19.

Schizophr Res

April 2024

Department of Psychiatry, University of Toronto, 250 College St, Toronto, ON M5T 1R8, Canada; Li Ka Shing Knowledge Institute, St. Michael's Hospital, 30 Bond Street, Toronto, ON M5B 1W8, Canada.

View Article and Find Full Text PDF

Background: Evening primrose oil (EPO), extracted from the seeds of Oenothera biennis, has gained attention for its therapeutic effects in various inflammatory conditions.

Method: We performed a systematic search in multiple databases and defined the inclusion criteria based on the following PICOs: P: Patients with a form of inflammatory condition, I: EPO, C: Placebo or other therapeutic interventions, O: changes in inflammatory markers or patients' symptoms; S: randomized controlled trials. The quality of the RCTs was evaluated using Cochrane's RoB tool.

View Article and Find Full Text PDF